Skip to main content

Table 6 Pearson correlation (bolded) and 95% CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD and stroke pathophysiology

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD and stroke risk factors Proteomic marker
  B2M ORM1 THBS1 CFD IGFBP1 IGFBP2 IGFBP4 IGFBP6 HPX
Lipids          
 HDL-C -0.16 -0.23 -0.10 -0.25 0.22 0.52 -0.25 -0.18 -0.21
(-0.27, -0.05) (-0.36, -0.09) (-0.24, 0.06) (-0.38, -0.11) (0.08, 0.36) (0.37, 0.64) (-0.41, -0.07) (-0.36, 0.01) (-0.38, -0.03)
 LDL-C -0.04 0.04 0.09 -0.01 -0.05 -0.15 0.01 0.02 0.14
(-0.15, 0.08) (-0.10, 0.19) (-0.06, 0.24) (-0.16, 0.13) (-0.19, 0.10) (-0.32, 0.04) (-0.18, 0.19) (-0.17, 0.21) (-0.04, 0.32)
Inflammatory markers          
 CRP -0.04 0.02 0.12 -0.04 0.05 -0.11 -0.02 -0.04 0.13
(-0.15, 0.08) (-0.12, 0.17) (-0.03, 0.27) (-0.18, 0.11) (-0.10, 0.19) (-0.28, 0.08) (-0.21, 0.16) (-0.23, 0.15) (-0.06, 0.30)
 IL-6 0.09 0.30 0.09 0.05 -0.11 -0.16 0.30 0.21 0.23
(-0.03, 0.20) (0.16, 0.43) (-0.07, 0.24) (-0.10, 0.20) (-0.25, 0.04) (-0.34, 0.03) (0.12, 0.46) (0.01, 0.39) (0.05, 0.40)
 MMP-9 0.08 0.30 -0.06 0.11 -0.06 -0.20 0.06 0.09 0.07
(-0.03, 0.20) (0.16, 0.43) (-0.21, 0.10) (-0.03, 0.26) (-0.20, 0.09) (-0.37, -0.01) (-0.12, 0.24) (-0.11, 0.27) (-0.11, 0.25)
Thrombosis and other blood markers          
 Factor VIII 0.21 0.14 0.06 -0.02 0.08 -0.11 0.23 0.19 0.12
(0.10, 0.32) (0.00, 0.28) (-0.10, 0.21) (-0.16, 0.12) (-0.07, 0.22) (-0.29, 0.08) (0.05, 0.39) (0.00, 0.37) (-0.06, 0.30)
 Factor 1.2 0.01 -0.04 -0.02 0.08 0.09 0.06 -0.02 0.06 0.31
(-0.10, 0.13) (-0.18, 0.10) (-0.18, 0.13) (-0.07, 0.22) (-0.06, 0.23) (-0.13, 0.24) (-0.20, 0.16) (-0.13, 0.25) (0.14, 0.47)
 D-Dimer -0.02 0.15 -0.10 0.08 0.11 -0.04 0.00 0.00 0.15
(-0.14, 0.10) (0.00, 0.29) (-0.26, 0.06) (-0.07, 0.23) (-0.04, 0.26) (-0.23, 0.15) (-0.19, 0.18) (-0.19, 0.20) (-0.04, 0.32)
 vWF 0.13 0.22 0.08 0.36 -0.01 0.15 0.18 0.09 0.06
(0.02, 0.24) (0.07, 0.35) (-0.22, 0.08) (0.23, 0.48) (-0.16, 0.13) (-0.03, 0.33) (0.00, 0.35) (-0.10, 0.28) (-0.13, 0.24)
 Insulin 0.23 -0.03 -0.01 0.19 -0.04 0.02 0.29 0.23 0.04
(0.12, 0.33) (-0.17, 0.11) (-0.16, 0.14) (0.05, 0.32) (-0.18, 0.11) (-0.16, 0.21) (0.11, 0.44) (0.04, 0.40) (-0.14, 0.22)
 Glucose 0.03 0.17 0.02 0.24 -0.44 -0.13 0.29 0.28 0.26
(-0.08, 0.15) (0.02, 0.31) (-0.14, 0.17) (0.10, 0.38) (-0.55, -0.31) (-0.31, 0.07) (0.10, 0.45) (0.08, 0.45) (0.07, 0.43)
 WBC 0.01 0.02 0.06 0.02 -0.10 -0.30 0.09 0.21 0.11
(-0.10, 0.12) (-0.12, 0.17) (-0.09, 0.21) (-0.12, 0.16) (-0.24, 0.04) (-0.46, -0.12) (-0.10, 0.27) (0.02, 0.39) (-0.08, 0.29)
Blood pressure          
 Systolic BP 0.08 0.10 0.17 0.04 -0.03 -0.25 0.00 0.17 0.14
(-0.04, 0.19) (-0.04, 0.24) (0.02, 0.32) (-0.11, 0.18) (-0.17, 0.12) (-0.42, -0.07) (-0.18, 0.18) (-0.02, 0.35) (-0.04, 0.31)
 Diastolic BP 0.18 0.08 -0.11 0.19 0.00 -0.06 0.18 0.18 0.05
  (0.08, 0.28) (-0.06, 0.22) (-0.25, 0.05) (0.05, 0.32) (-0.15, 0.14) (-0.21, 0.09) (0.03, 0.32) (0.03, 0.33) (-0.10, 0.19)
  1. Correlations are based on data from 357 controls drawn from the placebo groups of the WHI postmenopausal HT trials of estrogen plus progestin and estrogen-alone. Estimated correlations are bolded for ease of viewing.
  2. BP: blood pressure; CRP: C-reactive protein; Factor 1.2: prothrombin fragment 1.2; Factor VIII: clotting factor eight; HDL-C: high-density lipoprotein cholesterol; IL-6: interleukin 6; LDL-C: low-density lipoprotein cholesterol; MMP-9: matrix metallaprotinase-9; vWF: von villebrand factor; WBC: total leukocyte count; WHI: Women’s Health Initiative.